GLY-230

GLY-230 is an orally active compound. GLY-230 can inhibit nonenzymatic glycation and reduce glycated albumin. GLY-230 can reduce brain Aβ42 levels. GLY-230 can be used for the researches of metabolic and neurological disease, such as diabetic renal dysfunction[1][2].

Product Specifications

CAS Number

320777-05-7

UNSPSC

12352005

Target

Amyloid-β

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Metabolic Disease; Neurological Disease

Smiles

OC(CC(C=CC=C1)=C1NC2=CC(Cl)=CC=C2)=O

Molecular Formula

C14H12ClNO2

Molecular Weight

261.70

References & Citations

[1]Kennedy L, et al. Anti-glycation and anti-albuminuric effects of GLY-230 in human diabetes. Am J Nephrol. 2010;31 (2) :110-6.|[2]Cohen MP, et al. Reduction of Abeta42 in brains of transgenic APPswe mice by 2-3-chlorophenylaminophenylacetate. Clin Exp Pharmacol Physiol. 2009 Nov;36 (11) :1099-103.